Showing 6421-6430 of 9299 results for "".
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- Now Available at Pharmacies: Bayer's Finacea® Foam 15%https://practicaldermatology.com/news/now-available-at-pharmacies-bayers-finacea-azelaic-acid-foam-15/2458835/Bayer HealthCare’s Finacea® (azelaic acid) Foam, 15% in now available at pharmacies nationwide. Finacea Foam was FDA approved in July 2015 for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval was based on results
- Celgene Announces Results From Ongoing Phase 3 LIBERATE Trial of Otezla for Psoriasishttps://practicaldermatology.com/news/celgene-announces-results-from-ongoing-phase-3-liberate-trial-of-otezla-for-psoriasis/2458838/Results from Celgene Corporation’s ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis presented at 24th European Academy of Dermatology and Venereology show that half of psoriasis patients treated with oral Otezla achieved PASI
- LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-inc-announces-fda-approval-of-enstilar-foam-for-plaque-psoriasis/2458842/The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. In th
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design